Cardiovascular Adverse Events (CVAE) Associated With Second Generation Bruton Tyrosine Kinase (BTK) Inhibitor (BTKi) Therapy in Patients With Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta-Analysis

被引：0

作者：

Proskuriakova, Ekaterina ^{[1
]}

Shrestha, Dhan ^{[1
]}

Jasaraj, Ranjit ^{[1
]}

Mercado, Gustavo Espinoza ^{[1
]}

Wortstman, Josh ^{[1
]}

Kovalenko, Iulia ^{[2
]}

Khosla, Pam ^{[1
]}

机构：

[1] Mt Sinai Hosp, Chicago, IL USA

[2] UPMC, Harrisburg, PA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CLL; Bruton tyrosine kinase inhibitor; acalabrutinib; zanubrutinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-428

引用

页码：S327 / S328

页数：2

共 50 条

[31] Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials
Vidal, Liat
Gurion, Ronit
Ram, Ron
Raanani, Pia
Bairey, Osnat
Robak, Tadeusz
Gafter-Gvili, Anat
Shpilberg, Ofer
LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2047 - 2057
[32] Evaluation of the novel Bruton's tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C4815 mutated BTK.
Reiff, Sean David
Guinn, Daphne
Mantel, Rose
Smith, Lisa
Cheney, Carolyn
Johnson, Amy J.
Byrd, John C.
Woyach, Jennifer Ann
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] Cardiovascular Adverse Events Associated With First, Second and Third Generation Tyrosine Kinase Inhibitors Used in Treatment of Chronic Myeloid Leukemia
Mahida, Hetavi
Gharia, Bharatsinh
Ugoeke, Nene
Maludum, Obiora
Asif, Arif
Calderon, Dawn
CIRCULATION, 2018, 138
[34] Bruton tyrosine kinase inhibitors (BTKi) therapies in chronic lymphocytic leukemia (CLL): Review of multiple trials data for incidence of lymphocytosis and designation of partial response with lymphocytosis (PRL).
Narang, Jayant
Caplan, Christiana
Ludajic, Katarina
Ray, Sambit
Bajpai, Surabhi
Narang, Shweta
Jarecha, Rudresh
Sharma, Manish
Bohnsack, Oliver
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Pleyer, Christopher
Cohen, Jeffrey
Soto, Susan
Ali, Mir
Ahn, Inhye E.
Nierman, Pia
Valdez, Janet
Lotter, Jennifer
Superata, Jeanine
Tian, Xin
Wiestner, Adrian
Sun, Clare
BLOOD, 2019, 134
[36] Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia
Schliffke, Simon
Sivina, Mariela
Kim, Ekaterina
Thiele, Benjamin
Akyuz, Nuray
Falker-Gieske, Clemens
Thenhausen, Toni
Krohn-Grimberghe, Artus
Bokemeyer, Carsten
Jain, Nitin
Estrov, Zeev
Ferrajoli, Alessandra
Wierda, William G.
Keating, Michael J.
Burger, Jan A.
Binder, Mascha
BLOOD, 2016, 128 (22)
[37] RETRACTED ARTICLE: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis
Stefano Molica
Diana Giannarelli
Leukemia, 2021, 35 : 615 - 618
[38] Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis
Stefano Molica
Diana Giannarelli
Leukemia, 2023, 37 : 254 - 254
[39] Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Mohanavelu, Prahathishree
Mutnick, Mira
Mehra, Nidhi
White, Brandon
Kudrimoti, Sparsh
Hernandez Kluesner, Kaci
Chen, Xinyu
Nguyen, Tim
Horlander, Elaina
Thenot, Helena
Kota, Vamsi
Mitchell, Cassie S.
CANCERS, 2021, 13 (07)
[40] PHYSICIAN REPORTED TREATMENT ATTRIBUTES CONSIDERED IN FIRST-LINE AND PERCEPTIONS AROUND BRUTON TYROSINE KINASE INHIBITOR (BTKI) TREATMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) IN THE US
Jensen, C.
Ding, Z.
Greenwood, T.
Kluth, C.
Sanderson, I
Milloy, N.
Mavani, H.
Khan, W.
Qureshi, Z. P.
VALUE IN HEALTH, 2023, 26 (12) : S33 - S33

← 1 2 3 4 5 →